Coronary Intravascular Lithotripsy DRG 325 Reimbursement

DRG 325 covers inpatient admissions for coronary intravascular lithotripsy without intraluminal device placement, a procedure to treat heavily calcified coronary lesions. It matters for inpatient reimbursement because it groups cases by anticipated hospital resource use, influencing Centers for Medicare & Medicaid Services payment and billing classification.

DRG 325 Overview

DRG 325 covers inpatient encounters for coronary intravascular lithotripsy performed without placement of an intraluminal device, addressing calcified coronary lesions using pulsatile mechanical energy to facilitate angioplasty. This Diagnosis-Related Group is clinically focused on procedures to modify heavy vascular calcification that complicates percutaneous coronary interventions and can influence procedure complexity and resource use. For Centers for Medicare & Medicaid Services payment, DRG 325 groups cases with similar expected hospital resource consumption, affecting reimbursement rates and hospital billing classification. Accurate clinical documentation of the procedure and related diagnoses is essential for proper assignment to this Diagnosis-Related Group.

Early procedural safety and feasibility studies of coronary intravascular lithotripsy (IVL) as a standalone strategy for heavily calcified coronary lesions in patients presenting for percutaneous coronary intervention (PCI). These studies enroll adults with severe coronary artery calcification who are scheduled for PCI but in whom operators plan to avoid placing an intraluminal scaffold/device; primary endpoints focus on acute procedural success, device-related complications (vessel dissection, perforation), and need for bailout stenting. Evidence from this research informs interventional teams and payers on immediate resource use, procedural risk profiles, and the suitability of IVL-only approaches for select high-risk anatomy.
Comparative effectiveness trials evaluating IVL without intraluminal device versus traditional lesion preparation techniques (atherectomy, high-pressure ballooning) prior to drug-eluting stent placement in patients with complex calcified lesions. These studies target populations with multivessel disease or diabetes to compare angiographic lumen gain, procedural time, contrast use, and short-term major adverse cardiac events; subgroup analyses assess cases where operators attempt IVL-only strategies to avoid implanting additional metal. Results are relevant for clinicians and payers because they help define when IVL without device is noninferior or advantageous, potentially affecting procedure choice, device utilization, and downstream costs associated with repeat revascularization.
Post-procedure longitudinal outcomes and health economics studies following patients treated with coronary IVL without intraluminal device, focusing on medium- to long-term ischemic outcomes, symptom burden, rehospitalization rates, and total cost of care. These observational cohorts or registry-based analyses follow patients discharged after IVL-only procedures to quantify rates of recurrent angina, need for subsequent reintervention, and quality-of-life measures, while accounting for comorbidities common in this DRG population (elderly, chronic kidney disease). Payers and hospital administrators use this evidence to assess the durability of IVL-only strategies, their impact on readmission metrics and bundled payment outcomes, and to guide coverage and care-pathway decisions.

Early procedural safety and feasibility studies of coronary intravascular lithotripsy (IVL) as a standalone strategy for heavily calcified coronary lesions in patients presenting for percutaneous coronary intervention (PCI). These studies enroll adults with severe coronary artery calcification who are scheduled for PCI but in whom operators plan to avoid placing an intraluminal scaffold/device; primary endpoints focus on acute procedural success, device-related complications (vessel dissection, perforation), and need for bailout stenting. Evidence from this research informs interventional teams and payers on immediate resource use, procedural risk profiles, and the suitability of IVL-only approaches for select high-risk anatomy.
Comparative effectiveness trials evaluating IVL without intraluminal device versus traditional lesion preparation techniques (atherectomy, high-pressure ballooning) prior to drug-eluting stent placement in patients with complex calcified lesions. These studies target populations with multivessel disease or diabetes to compare angiographic lumen gain, procedural time, contrast use, and short-term major adverse cardiac events; subgroup analyses assess cases where operators attempt IVL-only strategies to avoid implanting additional metal. Results are relevant for clinicians and payers because they help define when IVL without device is noninferior or advantageous, potentially affecting procedure choice, device utilization, and downstream costs associated with repeat revascularization.
Post-procedure longitudinal outcomes and health economics studies following patients treated with coronary IVL without intraluminal device, focusing on medium- to long-term ischemic outcomes, symptom burden, rehospitalization rates, and total cost of care. These observational cohorts or registry-based analyses follow patients discharged after IVL-only procedures to quantify rates of recurrent angina, need for subsequent reintervention, and quality-of-life measures, while accounting for comorbidities common in this DRG population (elderly, chronic kidney disease). Payers and hospital administrators use this evidence to assess the durability of IVL-only strategies, their impact on readmission metrics and bundled payment outcomes, and to guide coverage and care-pathway decisions.

OpenPayer

Summary & Overview

Coronary Intravascular Lithotripsy without Intraluminal Device: Inpatient Reimbursement Overview

DRG 325 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes